BioSpace News Archive

Newron Pharmaceuticals S.p.A. announced that it is extending its Senior Management team through the appointment of Filippo Moriggia to the newly created position of Vice President of Operations.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals”), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil) for a sub-group of patients that in addition to ZYESAMI®, also received Remdesivir and continued to progress.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 2 new employees consisting of an aggregate of 135,000 stock options.

Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or “CCH”) in participants with adhesive capsulitis (AC) of the shoulder, commonly known as “frozen shoulder.”

A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD).

Biomea Fusion, Inc. (Nasdaq: BMEA), announced today that two BMF-219 preclinical abstracts were chosen for oral presentations at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Teva Pharmaceutical Industries Ltd. announced the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors.